ClinicalTrials.gg
Not yet recruitingNCT07761286Updated Aug 12, 2026

Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma

A Phase 1/2 interventional study of SYS6090 Injection + Bevacizumab Injection and SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection in HCC - Hepatocellular Carcinoma, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing bevacizumab in Carcinoma, Hepatocellular — 27 open to participants now, 37 under way, 5 of them phase 3. Bevacizumab · Carcinoma, Hepatocellular.

Planned enrollment
11th of 73
288 · median 45
Started
2026
with 5 others
Phase 1/2
6 of 73
5 open now
Primary completion
2029-09
later than 33 of 36 live
Registered
71st of 73
by date

Among the 73 studies testing bevacizumab in Carcinoma, Hepatocellular, this one is the 11th largest by planned enrollment, is one of 6 that started in 2026, is one of 6 in phase 1/2, reaches primary completion later than 33 of the 36 other live ones, and was the 71st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

27 of the 73 studies testing bevacizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

22 more — sign in →

By country, each count listing its studies:

All 27 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing bevacizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is an open-label, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of combination therapy with SYS6090 Injection in participants with hepatocellular carcinoma (HCC).

Read the detailed description

The study design consists of two phases. Phase Ib is a dose-escalation and dose-expansion study, with the primary objectives to evaluate the safety, tolerability and preliminary efficacy of SYS6090 combination therapy and identify the recommended dose for the combination regimen. Phase II is a randomized controlled trial (RCT) that with the objective to further assesses the efficacy and safety of SYS6090 combination therapy versus a positive control group.

03

Conditions studied

  • HCC - Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant voluntarily signs the form.
  2. Aged ≥18 years at the time of informed consent acquisition.
  3. Confirmed diagnosis of hepatocellular carcinoma (HCC) via histopathology, cytopathology, or clinical diagnosis in accordance with the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2026 Edition).
  4. Barcelona Clinic Liver Cancer (BCLC) Stage C; or BCLC Stage B unsuitable for curative surgery and/or locoregional therapy.
  5. score \<7 and no history of hepatic encephalopathy.
  6. No prior systemic anti-tumor therapy for HCC. Prior systemic therapy administered in the or adjuvant setting is permitted, provided that the time from the last dose of prior therapy to tumor recurrence is ≥6 months.
  7. At least one per Version 1.1. Lesions previously treated with interventional therapy, radiotherapy or ablation may be counted as measurable lesions if clear disease progression is documented per RECIST v1.1 and the lesion meets measurable lesion criteria.
  8. (ECOG) performance status ≤1.
  9. Expected survival ≥3 months.
  10. Adequate organ function as defined below:

    1. Hematology: ≥100×10⁹/L; ≥90 g/L; ≥1.5×10⁹/L (no blood transfusion, platelet transfusion or hematopoietic stimulating factor administered within 14 days prior to hematology testing at screening);
    2. Liver function: and ALT ≤5×; ≤1.5×ULN;
    3. Renal function: Ccr >50 mL/min (calculated by the formula); urine protein \<2+; participants with urine protein ≥2+ must have a 24-hour urine protein quantification \<1 g;
    4. Coagulation function: ≤1.5×ULN; INR ≤1.5×ULN. Participants receiving full-dose oral anticoagulants must maintain a stable dose for a minimum of 14 days;
    5. Albumin: ≥30 g/L (equivalent to ≥3.0 g/dL).
  11. Fertile eligible participants (male and female) must agree to use reliable methods together with their partners throughout the study period and for at least 7 months after the last study drug administration (hormonal contraceptives, barrier methods, or abstinence). Females of must have a negative serum pregnancy test within 7 days prior to enrollment.
  12. Willing and able to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma.
  2. Received any anti-tumor therapy (including chemotherapy, targeted therapy, immunotherapy, etc.) or any trial intervention within 4 weeks prior to the first study drug administration or within 5 half-lives of the most recent anti-tumor agent (whichever is shorter); or received Chinese patent medicines with anti-tumor indications, palliative radiotherapy, or locoregional therapy within 14 days prior to the first study drug administration.
  3. Underwent major visceral surgery (excluding core needle ) or sustained severe trauma within 4 weeks prior to the first study drug administration, or planned elective surgery during the study period.
  4. Received systemic or other agents within 14 days prior to the first study drug administration, except for the following scenarios: physiologic replacement doses of hydrocortisone or equivalent hormones (i.e., prednisone ≤10 mg/day or equivalent); topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids; short-course corticosteroids for prophylaxis (e.g., prophylaxis against contrast medium allergy).
  5. Received within 4 weeks prior to the first study drug administration. Note: Seasonal influenza vaccines are inactivated vaccines in general and are permitted. Intranasal influenza vaccines are live vaccines and are prohibited.
  6. Received strong inhibitors/inducers, or OATP1B1/OATP1B3 inhibitors within 14 days prior to the first study drug administration, or require continuous use of such agents throughout the study period.
  7. Adverse reactions from prior anti-tumor therapy have not recovered to Grade ≤1 per v6.0 (excluding toxicities judged by the Investigator to carry no safety risks, such as alopecia, Grade 2 peripheral neuropathy, hypothyroidism stabilized with hormone replacement therapy, etc.).
  8. History of or current central nervous system and/or carcinomatous meningitis; current untreated spinal cord compression (excluding participants with previously diagnosed treated spinal cord compression with documented clinically stable symptoms for more than 2 weeks prior to screening).
  9. Active infection requiring intravenous anti-infective therapy within 14 days prior to the first study drug administration.
  10. Symptomatic moderate or severe ascites within 14 days prior to the first dose or at screening (excluding minor ascites only visible on imaging without clinical symptoms); or uncontrolled moderate or larger pleural effusion or pericardial effusion.
  11. Tumor thrombus involving both the main portal vein and left/right portal branches simultaneously; tumor thrombus involving both the main portal vein and superior mesenteric vein simultaneously; or tumor thrombus involving the inferior vena cava.
  12. Esophageal or gastric variceal bleeding secondary to portal hypertension, or any life-threatening bleeding event within 6 months prior to the first study drug administration (including events requiring blood transfusion, surgery, locoregional intervention, or sustained medical treatment); known severe esophageal/gastric varices on endoscopy without definitive treatment within 3 months prior to the first study drug administration; other gastrointestinal bleeding events, active gastric or duodenal ulcer within 28 days prior to screening.
  13. History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or intestinal obstruction within 6 months prior to the first study drug administration.
  14. Presence of severe unhealed wounds or untreated fractures at screening.
  15. Current interstitial pneumonia/interstitial lung disease; prior history of interstitial pneumonia/interstitial lung disease requiring corticosteroid treatment; or other pulmonary conditions that may interfere with the identification and management of immune-related pulmonary toxicity, such as pulmonary fibrosis, organizing pneumonia, active pulmonary tuberculosis, etc.
  16. Active at screening [positive HBsAg or HBcAb with active viral replication (HBV DNA ≥2000 IU/mL)]; (positive Anti-HCV antibody with positive HCV RNA PCR); active syphilis infection (positive TP-Ab plus positive TRUST/RPR); infection; or concurrent co-infection with both hepatitis B and hepatitis C.
  17. History of severe cardiovascular and cerebrovascular diseases, including but not limited to:

    1. Class II or higher congestive heart failure, unstable angina, or myocardial infarction occurring within 6 months prior to the first study drug administration;
    2. Severe cardiac rhythm or conduction abnormalities requiring clinical intervention, such as ventricular arrhythmias, second- or third-degree atrioventricular block (participants may be eligible if the Investigator assesses no significant risks);
    3. Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy);
    4. history of prolongation, or QTcF (calculated via Fridericia's formula) > 480 ms at screening, or \< 50%;
    5. Arterial or venous thromboembolic events within 6 months prior to the first study drug administration, such as cerebrovascular accidents (including , cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, etc. Participants with stable thrombosis may be enrolled if the Investigator determines no cardiovascular risks.
    6. Uncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg).
  18. Active or recurrent disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for the following conditions:

    1. Autoimmune thyroid disease with clinically stable status;
    2. Type 1 diabetes managed with hormone replacement therapy;
    3. Autoimmune skin disorders well controlled with topical therapy (e.g., low-potency topical corticosteroids) without acute exacerbations requiring additional treatment within 12 months before screening (e.g., eczema, psoriasis, lichen simplex chronicus, or vitiligo involving \<10% of total body surface area).
  19. Prior immunotherapy complicated with Grade ≥3 immune-related adverse events (irAEs) or Grade ≥2 immune-related myocarditis (excluding stabilized immune-related endocrine abnormalities).
  20. Known to any component of the study treatment; history of hypersensitivity to premedications; or poorly controlled asthma (presentation of three or more asthma symptoms with partially controlled or uncontrolled status).
  21. Female participants who are pregnant or breastfeeding.
  22. History of other malignant tumors within 2 years prior to the first dose, or concurrent active malignant tumors (participants with cured localized tumors may be enrolled, including basal cell carcinoma of the skin, cutaneous squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the prostate, cervical carcinoma in situ, breast carcinoma in situ, etc.).
  23. Known alcohol or drug dependence; or other severe systemic medical conditions deemed by the Investigator to render the participant unsuitable for participation in this clinical study for any other reason.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    SYS6090+ BEV

    Drug: SYS6090 Injection + Bevacizumab Injection

  • Experimental
    SYS6090+SYS6043+ BEV

    Drug: SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection

  • Experimental
    BEV + SIN

    Drug: Bevacizumab Injection + Sintilimab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Evaluated incidence and severity of all Adverse Events (AEs) and Serious Adverse Events (SAEs) graded per NCI-CTCAE version 6.0, including abnormal laboratory tests, ECG parameters and vital signs from screening through end of safety follow-up.

    Time frame: Up to 2 years.

  2. Overall response rate (ORR)

    ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with at least one visit confirmed complete response (CR) or partial response (PR).

    Time frame: Up to 2 years.

  3. DLT;RP2D and MTD

    The Phase Ib study will explore the DLTs and MTD of SYS6090 combination therapy, and the RP2D will be determined based on the results from the Phase Ib study.

    Time frame: Up to 2 years.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2029, 36 months later.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 36 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 12, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2031
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07761286
Responsible party
Sponsor
First posted
Aug 12, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Aug 12, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-PD-1/IL-15 Fusion Protein JMT108 · Bevacizumab · Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 · Sintilimab

Start the discussion